Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - REVA Medical, Inc. | a58808e8vk.htm |
Exhibit 99.1
REVA Hires VP of Clinical and Regulatory Affairs
Sydney, Australia and San Diego, California (Friday 25 February 2011, AEDT) — REVA Medical,
Inc. (ASX: RVA) (“REVA” or the “Company”), which is developing a novel bioresorbable slide and lock
drug-eluting coronary stent called ReZolve™, is pleased to announce that Jeffrey A. Anderson has
joined the company’s executive team as Vice President of Clinical and Regulatory Affairs.
Mr. Anderson brings nearly 20 years of experience in the medical device industry and previously
served in the same capacity for the company from 2004 to 2008. Prior to returning to REVA, he held
positions of Vice President of Regulatory & Clinical Affairs and Vice President of Research and
Development for Neomend, Inc., where he led the FDA PMA process for the Company’s advanced
surgical-sealant products. Mr. Anderson brings a wealth of cardiovascular experience, having worked
at Abbott Vascular, Jomed, CRS Clinical Research and Medtronic.
The addition of Mr. Anderson affirms REVA’s commitment to building a world-class organization in
support of its business objectives. “We are delighted to welcome Jeff Anderson back to REVA to
provide his leadership and guidance to our clinical programs as we prepare for the start of the
Pilot Study, as well as more extensive clinical trials in the future,” commented the Company’s
Chairman and CEO, Robert Stockman.
REVA additionally announces the following activities:
REVA will file its Appendix 4E Preliminary Final Report with the ASX on 28 February 2011, AEDT (or
February 27, 2011 US EST).
REVA will participate in the Bioresorbable Scaffold Symposium featured at the Cardiovascular
Research Technologies conference in Washington, DC on 29 February 2011, AEDT (or February 28, 2011
US EST). Dr. Greg L. Kaluza from the Skirball Center for Cardiovascular Research, Cardiovascular
Research Foundation, will make the presentation.
A conference call with management is scheduled for 29 March 2011, AEDT (or Monday, March 28, 2011
US EDT) to discuss the Company’s financial results for the year ended December 31, 2010, and
business its outlook. Robert Stockman, Chairman and CEO, will host the call. Details on how to
access the conference call will be posted on the Company’s website ahead of the call.
About REVA
REVA is a development stage medical device company focused on the development and eventual
commercialisation of its proprietary, bioresorbable stent products. REVA’s lead product, the
ReZolve™ stent, combines REVA’s proprietary stent design with a proprietary polymer that is
metabolised and cleared from the body. The ReZolve™ stent is designed to offer full x-ray
visibility, clinically relevant sizing and a controlled and safe resorption rate. In
HEAD OFFICE: 5751 Copley Drive, Suite B, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9231 3322 • +61 9229 2727 (FAX) • ARBN 146 505 777
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9231 3322 • +61 9229 2727 (FAX) • ARBN 146 505 777
| REVA Medical, Inc. — ASX Announcement | Page 2 |
addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over
time, the ReZolve™ stent may reduce the incidence of late forming blood clots, or thrombosis, a
rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is
in the process of finalising the design of its ReZolve™ stent and intends to initiate a pilot human
clinical trial in the second quarter of 2011. REVA will require regulatory approval before it can
begin selling the ReZolve™ stent.
Forward-Looking Statements
This announcement contains forward-looking statements that are based on management’s beliefs,
assumptions and expectations and on information currently available to management. All statements
that address operating performance, events or developments that we expect or anticipate will occur
in the future are forward-looking statements, including without limitation our expectations with
respect to regulatory submissions and approvals such; our expectations with respect to our clinical
trials, including enrolment in or completion of our clinical trials; our expectations with respect
to the integrity or capabilities of our intellectual property position; our ability to
commercialize our existing products; our ability to develop and commercialize new products; and our
estimates regarding our capital requirements and financial performance, including profitability.
Management believes that these forward-looking statements are reasonable as and when made. You
should not place undue reliance on forward-looking statements because they speak only as of the
date when made. REVA does not assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
REVA may not actually achieve the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ materially from those disclosed
in the forward-looking statements. Forward-looking statements are subject to a number of risks and
uncertainties, described in “Risk Factors” in our Registration Statement on Form S-1 declared
effective by the United States Securities and Exchange Commission (the “SEC”) on November 15, 2010.
We may update our risk factors from time to time in “Part II, Item 1A. Risk Factors” in our
Periodic Reports or other current reports filed with the SEC.
Investor Enquiries:
|
Media Enquiries: | |
United States:
|
Cannings Corporate Communications | |
Cheryl Liberatore; REVA Director, Corporate Development
|
Michael Mullane | |
+1 858 966-3045
|
+ 61 414 590 296 | |
Australia: |
||
David Allen or Alan Taylor, Inteq Limited |
||
+61 2 9231 3322 |
HEAD OFFICE: 5751 Copley Drive, Suite B, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9231 3322 • +61 9229 2727 (FAX) • ARBN 146 505 777
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9231 3322 • +61 9229 2727 (FAX) • ARBN 146 505 777